Document Detail

Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: long term follow up and disease control after subsequent treatments.
MedLine Citation:
PMID:  17454634     Owner:  NLM     Status:  MEDLINE    
There are limited data regarding the long term follow up after thalidomide based regimen and the outcome of patients when they progress and they receive further treatment. We reassessed our original series of 43 patients with previously treated multiple myeloma who had received a pulsed cyclophosphamide, thalidomide, dexamethasone (CTD) regimen. Among the 43 patients, 14 did not respond to pulsed CTD and 29 (67%) achieved at least a partial response. The median PFS for all patients was 10 months. After a median follow up of 24 months (range 1 - 62), the 3 year PFS is 14% and 3 patients remain off treatment and without progression for 55+, 55+ and 56+ months respectively. Moreover, 28% of patients who progressed after CTD achieved a partial response after subsequent treatment which included thalidomide, bortezomib or lenalidomide. The median PFS of these patients was 5 months and the 1 year PFS was 20%. Furthermore, 31% of patients who had responded to CTD and then progressed (CTD sensitive) responded to subsequent treatment. We conclude that some patients enjoy long responses after CTD and that several patients who progress after CTD may respond to treatment with a novel agent-based regimen.
Maria Roussou; Athanasios Anagnostopoulos; Efstathios Kastritis; Charis Matsouka; Despina Barmparousi; Vasiliki Koutsoukou; Meletios A Dimopoulos
Related Documents :
12076394 - Interferon for interferon naive patients with chronic hepatitis c.
17007024 - Treatment of hepatitis c virus genotype 4 with peginterferon alfa-2a: impact of bilharz...
3298404 - A controlled trial of acyclovir in stable chronic hbsag, hbeag-positive carriers.
17724844 - Chronic hepatitis b: a wider range of therapeutic options.
23238684 - Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatme...
15872394 - Histomorphometric changes in the vessel wall at the site of amputation in diabetic pati...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  48     ISSN:  1042-8194     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-04-24     Completed Date:  2007-09-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  England    
Other Details:
Languages:  eng     Pagination:  754-8     Citation Subset:  IM    
Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cyclophosphamide / administration & dosage*
Dexamethasone / administration & dosage*
Disease Progression
Follow-Up Studies
Middle Aged
Multiple Myeloma / drug therapy*
Thalidomide / administration & dosage*
Treatment Outcome
Reg. No./Substance:
50-02-2/Dexamethasone; 50-18-0/Cyclophosphamide; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography...
Next Document:  Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced mu...